How Sponsors are Collaborating with Community Sites to Accelerate Trials and Improve Patient Access
The cost of running trials has grown 3x since 2000. These skyrocketing trial costs, paired with increased competition and growing trial complexity, demand a reinvention of the partnership between sponsors and sites. Some sponsors have tried to reverse these trends by relying even more on partnering with the largest sites, but this approach only limits access to patients.
To increase enrollment speed and improve patient access, sponsors are identifying new approaches to remove barriers currently preventing them from engaging with a wider variety of sites.
Join clinical leaders for a conversation on how sponsors are working with community sites to accelerate trial timelines and bring clinical research to each and every patient.
Learning Objectives:
- Current challenges facing sponsors looking to work with a wider variety of sites
- Effective strategies for sponsors to increase enrollment speed
- New approaches to engage with community sites and bring research to the patient
Speakers
Nathalie Riebel
Vice President, Clinical Operations
PDS Biotech
25+ years leading clinical operations to collaborate and achieve drug approval in Oncology. Repeated success guiding, cross-functional global clinical teams to achieve clinical deliverables and submission with optimal quality, efficiency and speed. Talent for leading innovative strategic programs that enhance corporate goals. Expert in developing process improvements, procedures and inspection readiness.
Jennifer Christofferson
Director, Site Management and Monitoring
AbbVie
Liz Beatty
Chief Strategy Officer
Inato
Panel Moderator
Liz is a decisive leader with unparalleled expertise in the digital clinical trials space and a clear track record of leveraging technology to increase clinical trial participation and enhance the clinical trial experience for sites and patients. She plays an important role in delivering on Inato’s mission to bring advanced technology, new doctors and their patients into the clinical research ecosystem to unlock the potential of the many unengaged research sites.
